Silence Therapeutics (SLNCF) Stock Price

Silence Therapeutics Price

OTC·CLOSED
6.53
​
Market closed

Silence Therapeutics stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Silence Therapeutics business model & stock analysis

Silence Therapeutics PLC is a British biotech company specializing in the development and commercialization of therapeutic RNAi technologies. The company was founded in 2004 and is headquartered in London. RNA interference (RNAi) is a method for specifically targeting and inhibiting genes using small RNA molecules that bind to the RNA of the target gene. This technology has great potential in developing new therapies for various diseases, such as cancer, genetic diseases, and viral diseases. Silence Therapeutics offers its technology platform in three different business areas: 1. Research and development: The company develops new RNAi-based therapeutics for various applications, such as cancer, fibrosis, or hemophilia. Silence Therapeutics already has several product candidates in clinical phases, such as SLN124, an RNAi medication for the treatment of hereditary amyloidosis. 2. Collaborations and licenses: Under this business area, the company works with various pharmaceutical and biotech companies to integrate its RNAi technology into their development programs. Silence Therapeutics can provide both its platform technology and specific RNAi libraries. 3. Production and technology services: Here, the company offers its customers services in RNAi production and the development of RNAi technologies. Silence Therapeutics can rely on its experience and expertise in the field of RNAi technology and support customers in developing tailored solutions. Silence Therapeutics has entered into various strategic partnerships with pharmaceutical and biotech companies in recent years to integrate its RNAi technology into their development programs. This includes a collaboration with AstraZeneca for the development of RNAi-based therapeutics for cardiovascular diseases. The company has also expanded its pipeline of RNAi therapeutics and has several product candidates in clinical phases. For example, Silence Therapeutics initiated a Phase II study for SLN360, an RNAi medication for the treatment of acute myeloid leukemia, in 2020. The company also holds a range of patents protecting its RNAi technology and has received several awards for its research and development work in recent years. Overall, Silence Therapeutics is a leading biotech company in the field of RNA interference. The company has successfully developed its own RNAi technology platform and offers its experience and expertise to other companies in the field of RNAi research and development.

Frequently asked questions about Silence Therapeutics

The business model of Silence Therapeutics PLC focuses on developing and commercializing innovative RNA-based therapeutics. As a leading biotechnology company, Silence Therapeutics utilizes its proprietary platform, called RNA interference (RNAi), to create new therapies that target and silence the genes responsible for disease progression. The company aims to address a wide range of medical conditions, including cardiovascular diseases, cancer, and genetic disorders, by leveraging its expertise in RNAi technology. By providing targeted treatments and partnering with pharmaceutical companies, Silence Therapeutics aims to improve patient outcomes and contribute to the advancement of personalized medicine.

Silence Therapeutics PLC is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Silence Therapeutics PLC in the market include companies such as Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and GalNAc-siRNA-focused therapeutics companies.

Silence Therapeutics PLC is a biotechnology company specializing in RNA therapeutics. Founded in 2002, the company focuses on developing innovative drugs using the mechanism of RNA interference (RNAi) to target and silence disease-causing genes. Silence Therapeutics has a strong background in RNAi research and has garnered expertise in developing proprietary delivery systems for efficient drug delivery. The company collaborates with various academic institutions, pharmaceutical companies, and research organizations to advance its pipeline of therapeutic candidates. With its commitment to revolutionizing healthcare through RNAi technology, Silence Therapeutics PLC has established itself as a leading player in the field of RNA therapeutics.

Silence Therapeutics PLC has achieved several significant milestones. The company successfully completed the initial public offering (IPO) on the London Stock Exchange in 2004, enabling it to raise funds for its groundbreaking RNA interference (RNAi) technology. In 2018, Silence Therapeutics entered into a transformational collaboration with Mallinckrodt Pharmaceuticals to develop and commercialize RNAi therapeutics for complement-mediated diseases. This collaboration further validates the potential of Silence Therapeutics' technology in addressing various diseases with unmet medical needs. The company also expanded its global footprint through partnerships with leading academic institutions and pharmaceutical companies. Silence Therapeutics PLC continues to demonstrate its commitment to advancing RNAi therapeutics and making a significant impact in the field of precision medicine.

Silence Therapeutics PLC is primarily present in various countries and regions worldwide. The company has a strong presence in Europe, particularly in the United Kingdom where its headquarters are based. Additionally, Silence Therapeutics has a significant presence in Germany and other European countries. The company also operates in the United States, with a growing presence and collaborations in the American market. Moreover, Silence Therapeutics is expanding its activities and partnerships globally, including in Asia and other regions.

Silence Therapeutics PLC represents values of innovation, scientific excellence, and a commitment to improving patient outcomes. The company's corporate philosophy revolves around utilizing RNA interference (RNAi) technology to silence disease-causing genes and develop targeted therapeutics. Silence Therapeutics PLC aims to revolutionize the treatment of various diseases, including cardiovascular, renal, and rare diseases, by harnessing the potential of RNAi. With a strong focus on research and development, the company strives to meet the unmet medical needs of patients worldwide through cutting-edge science and collaborations with leading organizations in the healthcare industry.

Converted at the current exchange rate, the Silence Therapeutics share trades at 5.95 EUR (6.53 USD).

The Silence Therapeutics share (SLNCF) is listed on 2 stock exchanges, including: London (SLN.L).

Silence Therapeutics PLC is a leading pharmaceutical company focusing on the development of RNA-based therapeutics. The company is headquartered in London, UK, with offices in Berlin and Redwood City, California. The business model of Silence Therapeutics is to utilize innovative RNA technologies to develop groundbreaking therapies for diseases that have been difficult to treat. RNA-based therapeutics are an emerging field of biotechnology and could play a significant role in disease treatment in the future. The company operates in three main divisions: research and development, partner programs, and clinical trials. In the research and development department, scientists and researchers from various fields work closely together to develop new RNA technologies and therapies. The company has an extensive technological platform that allows for the delivery of RNA molecules into cells and tissues to silence or influence specific genes. Silence Therapeutics also has partnerships with other pharmaceutical companies and universities to further develop its technologies and create new therapies. The partner programs aim to accelerate the development of RNA-based therapeutics and enable a broader application of this groundbreaking technology. The company also has a strong presence in the clinical phase of therapy development. It conducts clinical trials to test the efficacy and safety of its RNA technology-based drugs. A successful clinical phase is a crucial step towards drug approval and market launch. Silence Therapeutics is able to develop RNA technology-based therapeutics for a wide range of diseases. The company is currently focusing on cancer, rare diseases, and cardiovascular diseases. In cancer therapy, Silence Therapeutics is working on RNA-based therapies that selectively target tumor cells and hence can enhance the effects of chemotherapy and radiation. Another focus is on developing therapies for rare diseases, which are often caused by genetic defects. Here, RNA technology aims to provide an approach by influencing gene expression. Silence Therapeutics is also working on a new generation of RNA-based therapeutics for cardiovascular diseases. These therapies could help prevent or treat heart attacks and strokes by selectively influencing genes. In summary, Silence Therapeutics' business model revolves around the application and development of RNA technology to create groundbreaking therapies for difficult-to-treat diseases. The company utilizes an extensive technological platform to deliver RNA molecules into cells and tissues to influence or silence genes. With strong expertise in research and development, clinical trials, and partnerships, successful RNA-based therapeutics for cancer, rare diseases, and cardiovascular diseases can be achieved.

The revenue cannot currently be calculated for Silence Therapeutics.

The profit cannot currently be calculated for Silence Therapeutics.

The P/E ratio cannot be calculated for Silence Therapeutics at the moment.

The P/S cannot be calculated for Silence Therapeutics currently.

The Eulerpool Quality Score for Silence Therapeutics is 2/10.

The ISIN of Silence Therapeutics is GB00B9GTXM62. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Silence Therapeutics is A1T9PD. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Silence Therapeutics is SLNCF. The ticker symbol is used to trade Silence Therapeutics shares on the stock exchange.

Fair ValueTerminal
6.92 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Jan 5, 2010
ISIN
GB00B9GTXM62
Cusip
G8128Y157
Sedol
B9GTXM6
Market capitalization
308.25 M USDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
—
ROE (Return on Equity)
—
ROA (Return on Assets)
—
ROCE (Return on Capital Employed)
—
ROIC (Return on Invested Capital)
—
Last updated Nov 22, 2026, 3:16 PM

Silence Therapeutics Peer Group

Silence Therapeutics Ticker

LONDON STOCK EXCHANGE · SLN.LOTC · SLNCF

Silence Therapeutics FIGI

SLNCF:US · BBG000R53DP9SLNCF:PQ · BBG000R53LZ0SLNCF:UV · BBG000R53MM2SLN:XS · BBG000R9V764

All fundamentals and in-depth analysis of Silence Therapeutics

Our stock analysis for Silence Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Silence Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.